Compare BKU & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BKU | PBLS |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.5B |
| IPO Year | 2010 | 2026 |
| Metric | BKU | PBLS |
|---|---|---|
| Price | $43.04 | $28.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 6 |
| Target Price | ★ $46.82 | $41.40 |
| AVG Volume (30 Days) | 870.5K | ★ 1.1M |
| Earning Date | 10-21-2026 | 11-17-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | ★ 14.61 | N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $21,732,000.00 | N/A |
| Revenue This Year | $3.98 | N/A |
| Revenue Next Year | $4.93 | $300.17 |
| P/E Ratio | $24.18 | ★ N/A |
| Revenue Growth | ★ 7.45 | N/A |
| 52 Week Low | $38.01 | $22.66 |
| 52 Week High | $52.11 | $42.49 |
| Indicator | BKU | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 49.68 | 49.68 |
| Support Level | $41.36 | $26.42 |
| Resistance Level | $43.63 | $41.72 |
| Average True Range (ATR) | 1.02 | 2.39 |
| MACD | 0.22 | 0.64 |
| Stochastic Oscillator | 66.37 | 81.81 |
BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses. The company also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products including commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.